{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:13:00Z","timestamp":1786979580550,"version":"build-2736575974"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["FFC#4\/2022 Delegazione FFC Ricerca di Roma e della Franciacorta e Val Camonica"],"award-info":[{"award-number":["FFC#4\/2022 Delegazione FFC Ricerca di Roma e della Franciacorta e Val Camonica"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EU\u2019s NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases","award":["PE00000007"],"award-info":[{"award-number":["PE00000007"]}]},{"name":"EU\u2019s NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases","award":["INF-ACT"],"award-info":[{"award-number":["INF-ACT"]}]},{"name":"EU\u2019s NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases","award":["PE00000007"],"award-info":[{"award-number":["PE00000007"]}]},{"name":"EU\u2019s NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases","award":["INF-ACT"],"award-info":[{"award-number":["INF-ACT"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI176537"],"award-info":[{"award-number":["R01 AI176537"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004271","name":"Sapienza Universit\u00e0 di Roma","doi-asserted-by":"publisher","award":["RM12117A5D5A92A4"],"award-info":[{"award-number":["RM12117A5D5A92A4"]}],"id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cystic fibrosis (CF) is a rare disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a chloride channel with an important role in the airways. Despite the clinical efficacy of present modulators in restoring the activity of defective CFTR, there are patients who show persistent pulmonary infections, mainly due to\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    . Recently, we reported an unprecedented property of antimicrobial peptides i.e. Esc peptides, which consists in their ability to act as potentiators of CFTR carrying the most common mutation (the loss of phenylalanine 508) affecting protein folding, trafficking and gating. In this work, by electrophysiology experiments and computational studies, the capability of these peptides and de-novo designed analogs was demonstrated to recover the function of other mutated forms of CFTR which severely affect the channel gating (G551D and G1349D). This is presumably due to direct interaction of the peptides with the nucleotide binding domains (NBDs) of CFTR, followed by a novel local phenomenon consisting in distancing residues located at the cytosolic side of the NBDs interface, thus stabilizing the open conformation of the pore at its cytosolic end. The most promising peptides for the dual antimicrobial and CFTR potentiator activities were also shown to display antipseudomonal activity in conditions mimicking the CF pulmonary ion transport and mucus obstruction, with a higher efficacy than the clinically used colistin. These studies should assist in development of novel drugs for lung pathology in CF, with dual CFTR potentiator and large spectrum antibiotic activities.\n                  <\/jats:p>","DOI":"10.1007\/s00018-025-05633-9","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T11:10:25Z","timestamp":1742296225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Esc peptides and derivatives potentiate the activity of CFTR with gating defects and display antipseudomonal activity in cystic fibrosis-like lung disease"],"prefix":"10.1007","volume":"82","author":[{"given":"Loretta","family":"Ferrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriana","family":"Cappiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hexin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Casciaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Cappella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Bontempi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Corrente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Zara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Peter","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis J. V.","family":"Galietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5991-5868","authenticated-orcid":false,"given":"Maria Luisa","family":"Mangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"5633_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1165\/rcmb.2006-0082SF","volume":"35","author":"SH Randell","year":"2006","unstructured":"Randell SH, Boucher RC, University of North Carolina Virtual Lung G (2006) Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol 35:20\u201328. https:\/\/doi.org\/10.1165\/rcmb.2006-0082SF","journal-title":"Am J Respir Cell Mol Biol"},{"key":"5633_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1126\/science.1223012","volume":"337","author":"B Button","year":"2012","unstructured":"Button B, Cai LH, Ehre C, Kesimer M, Hill DB, Sheehan JK, Boucher RC, Rubinstein M (2012) A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 337:937\u2013941. https:\/\/doi.org\/10.1126\/science.1223012","journal-title":"Science"},{"key":"5633_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/0092-8674(92)90155-6","volume":"68","author":"CE Bear","year":"1992","unstructured":"Bear CE, Li CH, Kartner N, Bridges RJ, Jensen TJ, Ramjeesingh M, Riordan JR (1992) Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 68:809\u2013818. https:\/\/doi.org\/10.1016\/0092-8674(92)90155-6","journal-title":"Cell"},{"key":"5633_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature04712","volume":"440","author":"DC Gadsby","year":"2006","unstructured":"Gadsby DC, Vergani P, Csanady L (2006) The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 440:477\u2013483. https:\/\/doi.org\/10.1038\/nature04712","journal-title":"Nature"},{"key":"5633_CR5","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1074\/jbc.270.4.1711","volume":"270","author":"MR Carson","year":"1995","unstructured":"Carson MR, Travis SM, Welsh MJ (1995) The two nucleotide-binding domains of cystic fibrosis transmembrane conductance regulator (CFTR) have distinct functions in controlling channel activity. J Biol Chem 270:1711\u20131717","journal-title":"J Biol Chem"},{"key":"5633_CR6","doi-asserted-by":"publisher","first-page":"7689","DOI":"10.1074\/jbc.R100001200","volume":"276","author":"LS Ostedgaard","year":"2001","unstructured":"Ostedgaard LS, Baldursson O, Welsh MJ (2001) Regulation of the cystic fibrosis transmembrane conductance regulator Cl- channel by its R domain. J Biol Chem 276:7689\u20137692. https:\/\/doi.org\/10.1074\/jbc.R100001200","journal-title":"J Biol Chem"},{"key":"5633_CR7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nature03313","volume":"433","author":"P Vergani","year":"2005","unstructured":"Vergani P, Lockless SW, Nairn AC, Gadsby DC (2005) CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature 433:876\u2013880. https:\/\/doi.org\/10.1038\/nature03313","journal-title":"Nature"},{"key":"5633_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1085\/jgp.201010399","volume":"135","author":"MF Tsai","year":"2010","unstructured":"Tsai MF, Li M, Hwang TC (2010) Stable ATP binding mediated by a partial NBD dimer of the CFTR chloride channel. J Gen Physiol 135:399\u2013414. https:\/\/doi.org\/10.1085\/jgp.201010399","journal-title":"J Gen Physiol"},{"key":"5633_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1085\/jgp.201711946","volume":"150","author":"TC Hwang","year":"2018","unstructured":"Hwang TC, Yeh JT, Zhang J, Yu YC, Yeh HI, Destefano S (2018) Structural mechanisms of CFTR function and dysfunction. J Gen Physiol 150:539\u2013570. https:\/\/doi.org\/10.1085\/jgp.201711946","journal-title":"J Gen Physiol"},{"key":"5633_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.pupt.2010.02.001","volume":"23","author":"SM Rowe","year":"2010","unstructured":"Rowe SM, Pyle LC, Jurkevante A, Varga K, Collawn J, Sloane PA, Woodworth B, Mazur M, Fulton J, Fan L, Li Y, Fortenberry J, Sorscher EJ, Clancy JP (2010) DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. Pulm Pharmacol Ther 23:268\u2013278. https:\/\/doi.org\/10.1016\/j.pupt.2010.02.001","journal-title":"Pulm Pharmacol Ther"},{"key":"5633_CR11","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S2213-2600(16)30188-6","volume":"4","author":"FAL Marson","year":"2016","unstructured":"Marson FAL, Bertuzzo CS, Ribeiro JD (2016) Classification of CFTR mutation classes. Lancet Respir Med 4:e37\u2013e38. https:\/\/doi.org\/10.1016\/S2213-2600(16)30188-6","journal-title":"Lancet Respir Med"},{"key":"5633_CR12","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.3390\/ijms23073513","volume":"23","author":"C Harvey","year":"2022","unstructured":"Harvey C, Weldon S, Elborn S, Downey DG, Taggart C (2022) The Effect of CFTR modulators on airway infection in cystic fibrosis. Int J Mol Sci 23:3513. https:\/\/doi.org\/10.3390\/ijms23073513","journal-title":"Int J Mol Sci"},{"key":"5633_CR13","doi-asserted-by":"publisher","first-page":"1140034","DOI":"10.3389\/fgene.2023.1140034","volume":"14","author":"A Hosseini Nami","year":"2023","unstructured":"Hosseini Nami A, Kabiri M, Zafarghandi Motlagh F, Shirzadeh T, Fakhari N, Karimi A, Bagherian H, Jamali M, Younesikhah S, Shadman S, Zeinali R, Zeinali S (2023) Genetic attributes of Iranian cystic fibrosis patients: the diagnostic efficiency of CFTR mutations in over a decade. Front Genet 14:1140034. https:\/\/doi.org\/10.3389\/fgene.2023.1140034","journal-title":"Front Genet"},{"key":"5633_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1091\/mbc.E14-04-0935","volume":"27","author":"G Veit","year":"2016","unstructured":"Veit G, Avramescu RG, Chiang AN, Houck SA, Cai Z, Peters KW, Hong JS, Pollard HB, Guggino WB, Balch WE, Skach WR, Cutting GR, Frizzell RA, Sheppard DN, Cyr DM, Sorscher EJ, Brodsky JL, Lukacs GL (2016) From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell 27:424\u2013433. https:\/\/doi.org\/10.1091\/mbc.E14-04-0935","journal-title":"Mol Biol Cell"},{"key":"5633_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nsmb882","volume":"12","author":"K Du","year":"2005","unstructured":"Du K, Sharma M, Lukacs GL (2005) The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat Struct Mol Biol 12:17\u201325. https:\/\/doi.org\/10.1038\/nsmb882","journal-title":"Nat Struct Mol Biol"},{"key":"5633_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1113\/jphysiol.2005.099457","volume":"572","author":"L Cui","year":"2006","unstructured":"Cui L, Aleksandrov L, Hou YX, Gentzsch M, Chen JH, Riordan JR, Aleksandrov AA (2006) The role of cystic fibrosis transmembrane conductance regulator phenylalanine 508 side chain in ion channel gating. J Physiol 572:347\u2013358. https:\/\/doi.org\/10.1113\/jphysiol.2005.099457","journal-title":"J Physiol"},{"key":"5633_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/humu.10041","volume":"19","author":"JL Bobadilla","year":"2002","unstructured":"Bobadilla JL, Macek M Jr, Fine JP, Farrell PM (2002) Cystic fibrosis: a worldwide analysis of CFTR mutations\u2013correlation with incidence data and application to screening. Hum Mutat 19:575\u2013606. https:\/\/doi.org\/10.1002\/humu.10041","journal-title":"Hum Mutat"},{"key":"5633_CR18","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1016\/j.bcp.2004.02.022","volume":"67","author":"P Melin","year":"2004","unstructured":"Melin P, Thoreau V, Norez C, Bilan F, Kitzis A, Becq F (2004) The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein. Biochem Pharmacol 67:2187\u20132196. https:\/\/doi.org\/10.1016\/j.bcp.2004.02.022","journal-title":"Biochem Pharmacol"},{"key":"5633_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.molmed.2007.05.001","volume":"13","author":"RC Boucher","year":"2007","unstructured":"Boucher RC (2007) Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 13:231\u2013240. https:\/\/doi.org\/10.1016\/j.molmed.2007.05.001","journal-title":"Trends Mol Med"},{"key":"5633_CR20","doi-asserted-by":"publisher","first-page":"29ra31","DOI":"10.1126\/scitranslmed.3000928","volume":"2","author":"DA Stoltz","year":"2010","unstructured":"Stoltz DA, Meyerholz DK, Pezzulo AA, Ramachandran S, Rogan MP, Davis GJ, Hanfland RA, Wohlford-Lenane C, Dohrn CL, Bartlett JA, Nelson GA, Chang EH, Taft PJ, Ludwig PS, Estin M, Hornick EE, Launspach JL, Samuel M, Rokhlina T, Karp PH, Ostedgaard LS, Uc A, Starner TD, Horswill AR, Brogden KA, Prather RS, Richter SS, Shilyansky J, McCray PB, Zabner J Jr, Welsh MJ (2010) Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2:29ra31. https:\/\/doi.org\/10.1126\/scitranslmed.3000928","journal-title":"Sci Transl Med"},{"key":"5633_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1741-7015-9-32","volume":"9","author":"N Hoiby","year":"2011","unstructured":"Hoiby N (2011) Recent advances in the treatment of pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 9:32. https:\/\/doi.org\/10.1186\/1741-7015-9-32","journal-title":"BMC Med"},{"key":"5633_CR22","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2217\/fmb.10.125","volume":"5","author":"N Hoiby","year":"2010","unstructured":"Hoiby N, Ciofu O, Bjarnsholt T (2010) Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 5:1663\u20131674. https:\/\/doi.org\/10.2217\/fmb.10.125","journal-title":"Future Microbiol"},{"key":"5633_CR23","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/354526a0","volume":"354","author":"W Dalemans","year":"1991","unstructured":"Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, Crystal RG, Pavirani A, Lecocq JP, Lazdunski M (1991) Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 354:526\u2013528. https:\/\/doi.org\/10.1038\/354526a0","journal-title":"Nature"},{"key":"5633_CR24","doi-asserted-by":"publisher","first-page":"a009761","DOI":"10.1101\/cshperspect.a009761","volume":"3","author":"SM Rowe","year":"2013","unstructured":"Rowe SM, Verkman AS (2013) Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med 3:a009761. https:\/\/doi.org\/10.1101\/cshperspect.a009761","journal-title":"Cold Spring Harb Perspect Med"},{"key":"5633_CR25","doi-asserted-by":"publisher","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","volume":"5","author":"G Veit","year":"2020","unstructured":"Veit G, Roldan A, Hancock MA, Da Fonte DF, Xu H, Hussein M, Frenkiel S, Matouk E, Velkov T, Lukacs GL (2020) Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination. JCI Insight 5:e139983. https:\/\/doi.org\/10.1172\/jci.insight.139983","journal-title":"JCI Insight"},{"key":"5633_CR26","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/emmm.201302699","volume":"5","author":"N Odolczyk","year":"2013","unstructured":"Odolczyk N, Fritsch J, Norez C, Servel N, da Cunha MF, Bitam S, Kupniewska A, Wiszniewski L, Colas J, Tarnowski K, Tondelier D, Roldan A, Saussereau EL, Melin-Heschel P, Wieczorek G, Lukacs GL, Dadlez M, Faure G, Herrmann H, Ollero M, Becq F, Zielenkiewicz P, Edelman A (2013) Discovery of novel potent deltaf508-CFTR correctors that target the nucleotide binding domain. EMBO Mol Med 5:1484\u20131501. https:\/\/doi.org\/10.1002\/emmm.201302699","journal-title":"EMBO Mol Med"},{"key":"5633_CR27","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3390\/pharmaceutics12070616","volume":"12","author":"FA Almughem","year":"2020","unstructured":"Almughem FA, Aldossary AM, Tawfik EA, Alomary MN, Alharbi WS, Alshahrani MY, Alshehri AA (2020) Cystic fibrosis: overview of the current development trends and innovative therapeutic strategies. Pharmaceutics 12:616. https:\/\/doi.org\/10.3390\/pharmaceutics12070616","journal-title":"Pharmaceutics"},{"key":"5633_CR28","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jcf.2021.03.011","volume":"20","author":"G Veit","year":"2021","unstructured":"Veit G, Vaccarin C, Lukacs GL (2021) Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR. J Cyst Fibros 20:895\u2013898. https:\/\/doi.org\/10.1016\/j.jcf.2021.03.011","journal-title":"J Cyst Fibros"},{"key":"5633_CR29","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1128\/AAC.00904-16","volume":"60","author":"F Cappiello","year":"2016","unstructured":"Cappiello F, Di Grazia A, Segev-Zarko LA, Scali S, Ferrera L, Galietta L, Pini A, Shai Y, Di YP, Mangoni ML (2016) Esculentin-1a-derived peptides promote clearance of pseudomonas aeruginosa internalized in bronchial cells of cystic fibrosis patients and lung cell migration: biochemical properties and a plausible mode of action. Antimicrob Agents Chemother 60:7252\u20137262. https:\/\/doi.org\/10.1128\/AAC.00904-16","journal-title":"Antimicrob Agents Chemother"},{"key":"5633_CR30","doi-asserted-by":"publisher","first-page":"8548","DOI":"10.1038\/s41598-017-08361-8","volume":"7","author":"C Chen","year":"2017","unstructured":"Chen C, Mangoni ML, Di YP (2017) In vivo therapeutic efficacy of frog skin-derived peptides against pseudomonas aeruginosa-induced pulmonary infection. Sci Rep 7:8548. https:\/\/doi.org\/10.1038\/s41598-017-08361-8","journal-title":"Sci Rep"},{"key":"5633_CR31","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1021\/acs.biomac.8b01829","volume":"20","author":"B Casciaro","year":"2019","unstructured":"Casciaro B, d\u2019Angelo I, Zhang X, Loffredo MR, Conte G, Cappiello F, Quaglia F, Di YP, Ungaro F, Mangoni ML (2019) Poly (lactide- co-glycolide) nanoparticles for prolonged therapeutic efficacy of esculentin-1a-derived antimicrobial peptides against pseudomonas aeruginosa lung infection: in vitro and in vivo studies. Biomacromol 20:1876\u20131888. https:\/\/doi.org\/10.1021\/acs.biomac.8b01829","journal-title":"Biomacromol"},{"key":"5633_CR32","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3390\/pharmaceutics14112297","volume":"14","author":"F Cappiello","year":"2022","unstructured":"Cappiello F, Casciaro B, Loffredo MR, Puglisi E, Lin Q, Yang D, Conte G, d\u2019Angelo I, Ungaro F, Ferrera L, Barbieri R, Cresti L, Pini A, Di YP, Mangoni ML (2022) Pulmonary safety profile of esc peptides and Esc-peptide-loaded poly(lactide-co-glycolide) nanoparticles: a promising therapeutic approach for local treatment of lung infectious diseases. Pharmaceutics 14:2297. https:\/\/doi.org\/10.3390\/pharmaceutics14112297","journal-title":"Pharmaceutics"},{"key":"5633_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00018-021-04030-2","volume":"79","author":"L Ferrera","year":"2021","unstructured":"Ferrera L, Cappiello F, Loffredo MR, Puglisi E, Casciaro B, Botta B, Galietta LJV, Mori M, Mangoni ML (2021) Esc peptides as novel potentiators of defective cystic fibrosis transmembrane conductance regulator: an unprecedented property of antimicrobial peptides. Cell Mol Life Sci 79:67. https:\/\/doi.org\/10.1007\/s00018-021-04030-2","journal-title":"Cell Mol Life Sci"},{"key":"5633_CR34","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1021\/acsinfecdis.4c00130","volume":"10","author":"MR Loffredo","year":"2024","unstructured":"Loffredo MR, Casciaro B, Bellavita R, Troiano C, Brancaccio D, Cappiello F, Merlino F, Galdiero S, Fabrizi G, Grieco P, Stella L, Carotenuto A, Mangoni ML (2024) Strategic single-residue substitution in the antimicrobial peptide Esc(1\u201321) confers activity against staphylococcus aureus, including drug-resistant and biofilm phenotype. ACS Infect Dis 10:2403\u20132418. https:\/\/doi.org\/10.1021\/acsinfecdis.4c00130","journal-title":"ACS Infect Dis"},{"key":"5633_CR35","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1172\/JCI16112","volume":"110","author":"T Ma","year":"2002","unstructured":"Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, Verkman AS (2002) Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 110:1651\u20131658. https:\/\/doi.org\/10.1172\/JCI16112","journal-title":"J Clin Invest"},{"key":"5633_CR36","doi-asserted-by":"publisher","first-page":"C988","DOI":"10.1152\/ajpcell.1997.273.3.C988","volume":"273","author":"TC Hwang","year":"1997","unstructured":"Hwang TC, Wang F, Yang IC, Reenstra WW (1997) Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol 273:C988-998. https:\/\/doi.org\/10.1152\/ajpcell.1997.273.3.C988","journal-title":"Am J Physiol"},{"key":"5633_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jcf.2015.11.010","volume":"15","author":"LB Gottschalk","year":"2016","unstructured":"Gottschalk LB, Vecchio-Pagan B, Sharma N, Han ST, Franca A, Wohler ES, Batista DA, Goff LA, Cutting GR (2016) Creation and characterization of an airway epithelial cell line for stable expression of CFTR variants. J Cyst Fibros 15:285\u2013294. https:\/\/doi.org\/10.1016\/j.jcf.2015.11.010","journal-title":"J Cyst Fibros"},{"key":"5633_CR38","doi-asserted-by":"publisher","first-page":"eaay9669","DOI":"10.1126\/sciadv.aay9669","volume":"6","author":"N Pedemonte","year":"2020","unstructured":"Pedemonte N, Bertozzi F, Caci E, Sorana F, Di Fruscia P, Tomati V, Ferrera L, Rodriguez-Gimeno A, Berti F, Pesce E, Sondo E, Gianotti A, Scudieri P, Bandiera T, Galietta LJV (2020) Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel. Sci Adv 6:eaay9669. https:\/\/doi.org\/10.1126\/sciadv.aay9669","journal-title":"Sci Adv"},{"key":"5633_CR39","doi-asserted-by":"publisher","first-page":"628968","DOI":"10.3389\/fphar.2021.628968","volume":"12","author":"M Kato","year":"2021","unstructured":"Kato M, Takayama Y, Sunagawa M (2021) The calcium-activated chloride channel TMEM16A is Inhibitied by liquiritigenin. Front Pharmacol 12:628968. https:\/\/doi.org\/10.3389\/fphar.2021.628968","journal-title":"Front Pharmacol"},{"key":"5633_CR40","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3390\/pathogens10091177","volume":"10","author":"C Rumpf","year":"2021","unstructured":"Rumpf C, Lange J, Schwartbeck B, Kahl BC (2021) Staphylococcus aureus and cystic fibrosis-a close relationship. what can we learn from sequencing studies? Pathogens 10:1177. https:\/\/doi.org\/10.3390\/pathogens10091177","journal-title":"Pathogens"},{"key":"5633_CR41","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.cmi.2017.08.029","volume":"24","author":"C Chen","year":"2018","unstructured":"Chen C, Deslouches B, Montelaro RC, Di YP (2018) Enhanced efficacy of the engineered antimicrobial peptide WLBU2 via direct airway delivery in a murine model of pseudomonas aeruginosa pneumonia. Clin Microbiol Infect 24:547. https:\/\/doi.org\/10.1016\/j.cmi.2017.08.029","journal-title":"Clin Microbiol Infect"},{"key":"5633_CR42","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00226-19","author":"S Jiang","year":"2019","unstructured":"Jiang S, Deslouches B, Chen C, Di ME, Di YP (2019) Antibacterial properties and efficacy of a novel SPLUNC1-derived antimicrobial peptide, alpha4-short, in a murine model of respiratory infection. MBio. https:\/\/doi.org\/10.1128\/mBio.00226-19","journal-title":"MBio"},{"key":"5633_CR43","doi-asserted-by":"publisher","first-page":"101419","DOI":"10.1016\/j.xpro.2022.101419","volume":"3","author":"A Golec","year":"2022","unstructured":"Golec A, Pranke I, Scudieri P, Hayes K, Dreano E, Dunlevy F, Hatton A, Downey DG, Galietta L, Sermet I (2022) Isolation, cultivation, and application of primary respiratory epithelial cells obtained by nasal brushing, polyp samples, or lung explants. STAR Protoc 3:101419. https:\/\/doi.org\/10.1016\/j.xpro.2022.101419","journal-title":"STAR Protoc"},{"key":"5633_CR44","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nm1028","volume":"10","author":"M Mall","year":"2004","unstructured":"Mall M, Grubb BR, Harkema JR, O\u2019Neal WK, Boucher RC (2004) Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 10:487\u2013493. https:\/\/doi.org\/10.1038\/nm1028","journal-title":"Nat Med"},{"issue":"Suppl 2","key":"5633_CR45","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.1016\/S1569-1993(11)60021-0","volume":"10","author":"Z Zhou","year":"2011","unstructured":"Zhou Z, Duerr J, Johannesson B, Schubert SC, Treis D, Harm M, Graeber SY, Dalpke A, Schultz C, Mall MA (2011) The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease. J Cyst Fibros 10(Suppl 2):S172-182. https:\/\/doi.org\/10.1016\/S1569-1993(11)60021-0","journal-title":"J Cyst Fibros"},{"issue":"Suppl 40","key":"5633_CR46","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1002\/ppul.23242","volume":"50","author":"DP Nichols","year":"2015","unstructured":"Nichols DP, Chmiel JF (2015) Inflammation and its genesis in cystic fibrosis. Pediatr Pulmonol 50(Suppl 40):S39-56. https:\/\/doi.org\/10.1002\/ppul.23242","journal-title":"Pediatr Pulmonol"},{"key":"5633_CR47","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn JS (2016) Cystic fibrosis. Lancet 388:2519\u20132531. https:\/\/doi.org\/10.1016\/S0140-6736(16)00576-6","journal-title":"Lancet"},{"key":"5633_CR48","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","volume":"397","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg M, Haq IJ, Polineni D, Davies JC (2021) Cystic fibrosis. Lancet 397:2195\u20132211. https:\/\/doi.org\/10.1016\/S0140-6736(20)32542-3","journal-title":"Lancet"},{"key":"5633_CR49","doi-asserted-by":"publisher","first-page":"112631","DOI":"10.1016\/j.ejmech.2020.112631","volume":"204","author":"V Spano","year":"2020","unstructured":"Spano V, Venturini A, Genovese M, Barreca M, Raimondi MV, Montalbano A, Galietta LJV, Barraja P (2020) Current development of CFTR potentiators in the last decade. Eur J Med Chem 204:112631. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112631","journal-title":"Eur J Med Chem"},{"key":"5633_CR50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","volume":"185","author":"K Fiedorczuk","year":"2022","unstructured":"Fiedorczuk K, Chen J (2022) Mechanism of CFTR correction by type I folding correctors. Cell 185:158\u2013168. https:\/\/doi.org\/10.1016\/j.cell.2021.12.009","journal-title":"Cell"},{"key":"5633_CR51","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","volume":"10","author":"M Lopes-Pacheco","year":"2019","unstructured":"Lopes-Pacheco M (2019) CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol 10:1662. https:\/\/doi.org\/10.3389\/fphar.2019.01662","journal-title":"Front Pharmacol"},{"key":"5633_CR52","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1016\/j.cell.2024.04.046","volume":"187","author":"F Liu","year":"2024","unstructured":"Liu F, Kaplan AL, Levring J, Einsiedel J, Tiedt S, Distler K, Omattage NS, Kondratov IS, Moroz YS, Pietz HL, Irwin JJ, Gmeiner P, Shoichet BK, Chen J (2024) Structure-based discovery of CFTR potentiators and inhibitors. Cell 187:3712\u20133725. https:\/\/doi.org\/10.1016\/j.cell.2024.04.046","journal-title":"Cell"},{"key":"5633_CR53","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00039.2023","author":"YP Di","year":"2024","unstructured":"Di YP, Kuhn JM, Mangoni ML (2024) Lung antimicrobial proteins and peptides: from host defense to therapeutic strategies. Physiol Rev. https:\/\/doi.org\/10.1152\/physrev.00039.2023","journal-title":"Physiol Rev"},{"key":"5633_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1085\/jgp.20028673","volume":"121","author":"P Vergani","year":"2003","unstructured":"Vergani P, Nairn AC, Gadsby DC (2003) On the mechanism of MgATP-dependent gating of CFTR Cl- channels. J Gen Physiol 121:17\u201336. https:\/\/doi.org\/10.1085\/jgp.20028673","journal-title":"J Gen Physiol"},{"key":"5633_CR55","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1085\/jgp.201711886","volume":"149","author":"HI Yeh","year":"2017","unstructured":"Yeh HI, Sohma Y, Conrath K, Hwang TC (2017) A common mechanism for CFTR potentiators. J Gen Physiol 149:1105\u20131118. https:\/\/doi.org\/10.1085\/jgp.201711886","journal-title":"J Gen Physiol"},{"key":"5633_CR56","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41586-023-05854-7","volume":"616","author":"J Levring","year":"2023","unstructured":"Levring J, Terry DS, Kilic Z, Fitzgerald G, Blanchard SC, Chen J (2023) CFTR function, pathology and pharmacology at single-molecule resolution. Nature 616:606\u2013614. https:\/\/doi.org\/10.1038\/s41586-023-05854-7","journal-title":"Nature"},{"key":"5633_CR57","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1126\/science.aaw7611","volume":"364","author":"F Liu","year":"2019","unstructured":"Liu F, Zhang Z, Levit A, Levring J, Touhara KK, Shoichet BK, Chen J (2019) Structural identification of a hotspot on CFTR for potentiation. Science 364:1184\u20131188. https:\/\/doi.org\/10.1126\/science.aaw7611","journal-title":"Science"},{"key":"5633_CR58","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature24652","volume":"552","author":"C Paulino","year":"2017","unstructured":"Paulino C, Kalienkova V, Lam AKM, Neldner Y, Dutzler R (2017) Activation mechanism of the calcium-activated chloride channel TMEM16A revealed by cryo-EM. Nature 552:421\u2013425. https:\/\/doi.org\/10.1038\/nature24652","journal-title":"Nature"},{"key":"5633_CR59","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1126\/science.ade2216","volume":"378","author":"K Fiedorczuk","year":"2022","unstructured":"Fiedorczuk K, Chen J (2022) Molecular structures reveal synergistic rescue of delta508 CFTR by trikafta modulators. Science 378:284\u2013290. https:\/\/doi.org\/10.1126\/science.ade2216","journal-title":"Science"},{"key":"5633_CR60","doi-asserted-by":"publisher","first-page":"12757","DOI":"10.1073\/pnas.1815287115","volume":"115","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Liu F, Chen J (2018) Molecular structure of the ATP-bound, phosphorylated human CFTR. Proc Natl Acad Sci U S A 115:12757\u201312762. https:\/\/doi.org\/10.1073\/pnas.1815287115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5633_CR61","doi-asserted-by":"publisher","first-page":"167929","DOI":"10.1016\/j.jmb.2022.167929","volume":"435","author":"M Ravatin","year":"2023","unstructured":"Ravatin M, Odolczyk N, Servel N, Guijarro JI, Tagat E, Chevalier B, Baatallah N, Corringer PJ, Lukacs GL, Edelman A, Zielenkiewicz P, Chambard JM, Hinzpeter A, Faure G (2023) Design of crotoxin-based peptides with potentiator activity targeting the deltaF508NBD1 cystic fibrosis transmembrane conductance regulator. J Mol Biol 435:167929. https:\/\/doi.org\/10.1016\/j.jmb.2022.167929","journal-title":"J Mol Biol"},{"key":"5633_CR62","doi-asserted-by":"publisher","first-page":"eabl6328","DOI":"10.1126\/scitranslmed.abl6328","volume":"14","author":"A Ghigo","year":"2022","unstructured":"Ghigo A, Murabito A, Sala V, Pisano AR, Bertolini S, Gianotti A, Caci E, Montresor A, Premchandar A, Pirozzi F, Ren K, Della Sala A, Mergiotti M, Richter W, de Poel E, Matthey M, Caldrer S, Cardone RA, Civiletti F, Costamagna A, Quinney NL, Butnarasu C, Visentin S, Ruggiero MR, Baroni S, Crich SG, Ramel D, Laffargue M, Tocchetti CG, Levi R, Conti M, Lu XY, Melotti P, Sorio C, De Rose V, Facchinetti F, Fanelli V, Wenzel D, Fleischmann BK, Mall MA, Beekman J, Laudanna C, Gentzsch M, Lukacs GL, Pedemonte N, Hirsch E (2022) A PI3Kgamma mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases. Sci Transl Med 14:eabl6328. https:\/\/doi.org\/10.1126\/scitranslmed.abl6328","journal-title":"Sci Transl Med"},{"key":"5633_CR63","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00237-20","author":"KJ Brao","year":"2020","unstructured":"Brao KJ, Wille BP, Lieberman J, Ernst RK, Shirtliff ME, Harro JM (2020) Scnn1b-transgenic BALB\/c mice as a model of pseudomonas aeruginosa infections of the cystic fibrosis lung. Infect Immun. https:\/\/doi.org\/10.1128\/IAI.00237-20","journal-title":"Infect Immun"},{"key":"5633_CR64","doi-asserted-by":"publisher","first-page":"7234","DOI":"10.1038\/s41598-019-43652-2","volume":"9","author":"AR Habib","year":"2019","unstructured":"Habib AR, Kajbafzadeh M, Desai S, Yang CL, Skolnik K, Quon BS (2019) A systematic review of the clinical efficacy and safety of CFTR modulators in cystic fibrosis. Sci Rep 9:7234. https:\/\/doi.org\/10.1038\/s41598-019-43652-2","journal-title":"Sci Rep"},{"key":"5633_CR65","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2021.1951705","author":"G Sulis","year":"2021","unstructured":"Sulis G, Sayood S, Gandra S (2021) Antimicrobial resistance in low- and middle-income countries: current status and future directions. Expert Rev Anti Infect Ther. https:\/\/doi.org\/10.1080\/14787210.2021.1951705","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5633_CR66","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41419-022-05398-0","volume":"13","author":"G Bontempi","year":"2022","unstructured":"Bontempi G, Terri M, Garbo S, Montaldo C, Mariotti D, Bordoni V, Valente S, Zwergel C, Mai A, Marchetti A, Domenici A, Mene P, Battistelli C, Tripodi M, Strippoli R (2022) Restoration of WT1\/miR-769-5p axis by HDAC1 inhibition promotes MMT reversal in mesenchymal-like mesothelial cells. Cell Death Dis 13:965. https:\/\/doi.org\/10.1038\/s41419-022-05398-0","journal-title":"Cell Death Dis"},{"key":"5633_CR67","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/2211068214561025","volume":"20","author":"B Srinivasan","year":"2015","unstructured":"Srinivasan B, Kolli AR, Esch MB, Abaci HE, Shuler ML, Hickman JJ (2015) TEER measurement techniques for in vitro barrier model systems. J Lab Autom 20:107\u2013126. https:\/\/doi.org\/10.1177\/2211068214561025","journal-title":"J Lab Autom"},{"key":"5633_CR68","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.chembiol.2018.04.010","volume":"25","author":"E Sondo","year":"2018","unstructured":"Sondo E, Falchi F, Caci E, Ferrera L, Giacomini E, Pesce E, Tomati V, Mandrup Bertozzi S, Goldoni L, Armirotti A, Ravazzolo R, Cavalli A, Pedemonte N (2018) Pharmacological inhibition of the ubiquitin ligase RNF5 rescues F508del-CFTR in cystic fibrosis airway epithelia. Cell Chem Biol 25:891\u2013905. https:\/\/doi.org\/10.1016\/j.chembiol.2018.04.010","journal-title":"Cell Chem Biol"},{"key":"5633_CR69","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3389\/fphar.2018.01464","volume":"9","author":"E Pesce","year":"2018","unstructured":"Pesce E, Sondo E, Ferrera L, Tomati V, Caci E, Scudieri P, Musante I, Renda M, Baatallah N, Servel N, Hinzpeter A, di Bernardo D, Pedemonte N, Galietta LJV (2018) The autophagy inhibitor spautin-1 antagonizes rescue of mutant CFTR through an autophagy-independent and USP13-mediated mechanism. Front Pharmacol 9:1464. https:\/\/doi.org\/10.3389\/fphar.2018.01464","journal-title":"Front Pharmacol"},{"key":"5633_CR70","doi-asserted-by":"publisher","first-page":"pgac288","DOI":"10.1093\/pnasnexus\/pgac288","volume":"2","author":"M Genovese","year":"2023","unstructured":"Genovese M, Guidone D, Buccirossi M, Borrelli A, Rodriguez-Gimeno A, Bertozzi F, Bandiera T, Galietta LJV (2023) Pharmacological potentiators of the calcium signaling cascade identified by high-throughput screening. PNAS Nexus 2:pgac288. https:\/\/doi.org\/10.1093\/pnasnexus\/pgac288","journal-title":"PNAS Nexus"},{"key":"5633_CR71","doi-asserted-by":"publisher","first-page":"064101","DOI":"10.1063\/5.0019054","volume":"153","author":"AT Bogetti","year":"2020","unstructured":"Bogetti AT, Piston HE, Leung JMG, Cabalteja CC, Yang DT, DeGrave AJ, Debiec KT, Cerutti DS, Case DA, Horne WS, Chong LT (2020) A twist in the road less traveled: The AMBER ff15ipq-m force field for protein mimetics. J Chem Phys 153:064101. https:\/\/doi.org\/10.1063\/5.0019054","journal-title":"J Chem Phys"},{"key":"5633_CR72","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25:1157\u20131174. https:\/\/doi.org\/10.1002\/jcc.20035","journal-title":"J Comput Chem"},{"key":"5633_CR73","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1021\/acs.jcim.0c00613","volume":"60","author":"TS Lee","year":"2020","unstructured":"Lee TS, Allen BK, Giese TJ, Guo Z, Li P, Lin C, McGee TD Jr, Pearlman DA, Radak BK, Tao Y, Tsai HC, Xu H, Sherman W, York DM (2020) Alchemical binding free energy calculations in AMBER20: advances and best practices for drug discovery. J Chem Inf Model 60:5595\u20135623. https:\/\/doi.org\/10.1021\/acs.jcim.0c00613","journal-title":"J Chem Inf Model"},{"key":"5633_CR74","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1021\/ct400341p","volume":"9","author":"DR Roe","year":"2013","unstructured":"Roe DR, Cheatham TE 3rd (2013) PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 9:3084\u20133095. https:\/\/doi.org\/10.1021\/ct400341p","journal-title":"J Chem Theory Comput"},{"key":"5633_CR75","doi-asserted-by":"publisher","first-page":"6516","DOI":"10.1038\/s41598-019-42751-4","volume":"9","author":"J Simonin","year":"2019","unstructured":"Simonin J, Bille E, Crambert G, Noel S, Dreano E, Edwards A, Hatton A, Pranke I, Villeret B, Cottart CH, Vrel JP, Urbach V, Baatallah N, Hinzpeter A, Golec A, Touqui L, Nassif X, Galietta LJV, Planelles G, Sallenave JM, Edelman A, Sermet-Gaudelus I (2019) Airway surface liquid acidification initiates host defense abnormalities in cystic fibrosis. Sci Rep 9:6516. https:\/\/doi.org\/10.1038\/s41598-019-42751-4","journal-title":"Sci Rep"},{"key":"5633_CR76","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3390\/biom13071028","volume":"13","author":"F Cappiello","year":"2023","unstructured":"Cappiello F, Verma S, Lin X, Moreno IY, Casciaro B, Dutta D, McDermott AM, Willcox M, Coulson-Thomas VJ, Mangoni ML (2023) Novel peptides with dual properties for treating pseudomonas aeruginosa keratitis: antibacterial and corneal wound healing. Biomolecules 13:1028. https:\/\/doi.org\/10.3390\/biom13071028","journal-title":"Biomolecules"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05633-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-025-05633-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05633-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T11:10:34Z","timestamp":1742296234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-025-05633-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5633"],"URL":"https:\/\/doi.org\/10.1007\/s00018-025-05633-9","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study on bronchial cells to investigate the effect of the peptides on CFTR was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the IRCCS Istituto Giannina Gaslini, Genova (24 September 2010; Number: 182). Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study on animals was conducted according to a protocol (protocol 23083347) approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Pittsburgh based on the NIH guide for the care and use of laboratory animals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and\/or animal participants"}}],"article-number":"121"}}